Atebrioz (zilurgisertib)
Mirum Pharmaceuticals (MIRM)
ApprovedSep 25, 2026
Marketer take
Enters fibrodysplasia ossificans progressiva alongside Sohonos and Regeneron's Pasatru (approved five weeks earlier), so a tiny specialist community will see three-way differentiation messaging, starting with Atebrioz's label down to age 12.
- Sponsor company
- Mirum Pharmaceuticals (MIRM)
- Indication
- To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Therapeutic area
- Rare disease
- Event
- FDA approval
- Date
- Sep 25, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?